AATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for chronic respiratory diseases. Rüdiger Jankowsky, CEO, and Gabriele Matschiner, Chief Development Officer, explain the development program, the choice of bronchiectasis and the upcoming Phase 1b/2a trial.
Perfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially proven. As global demand for high quality, cost competitive biosimilars accelerates, perfusion stands ready as the technology built for this moment.
For CDMOs, flexible upstream platforms can help streamline process development while maintaining reproducibility and continuity across scales.
Justyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization readiness.
Customized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.
Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global leadership.
In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a patent application once the claims are deemed allowable. The adaptation of the description is an extensive and very costly writing exercise. There was inconsistent case law of the Boards of Appeal (TBoA) on whether and to what extent said adaptation is necessary. The Enlarged Board of Appeal (EBoA) has now decided, and it changes for the worse for the practitioner.
As artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026.
The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.
Join us for the 2nd BIO-Europe in Cologne, Germany, November 9–11, 2026, the premier biopharma partnering event now transformed into a comprehensive forum for biotech leaders.
SLAS
EBD Group/Informa